Presta M, Mazzocchi C, Ziliani S, Zavanella T, Ragnotti G
Chem Biol Interact. 1984 Dec;52(2):203-12. doi: 10.1016/0009-2797(84)90073-5.
Liver alterations occurring after 1, 6 or 10 days of treatment with the hepatocarcinogen beta-blocker DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butyl-amino-propan-2-ol (ZAMI 1305) were studied in male and female Wistar rats. In agreement with its sex-dependent oncogenicity, ZAMI 1305 administration causes DNA damage in the liver of the female but not of the male rat, with the only exception of 2 out of 4 males treated for 6 days. In female rat, the amount of DNA damage increases from 1 to 6 days of treatment, being unchanged at 10 days; a small portion of DNA is however damaged. ZAMI 1305 administration to female rat induces also: (i) an increase of the relative liver weight, of the DNA and RNA synthesizing activity; (ii) a decrease of the number of hepatocytes in mitosis; (iii) a minimal oval cell hyperplasia. When the same parameters were studied in ZAMI 1305-treated male rats, they were unaffected or changed to a less extent in respect to female rats.
在用肝癌致癌物β受体阻滞剂DL-1-(2-硝基-3-甲基-苯氧基)-3-叔丁基氨基-丙-2-醇（ZAMI 1305）治疗1天、6天或10天后，对雄性和雌性Wistar大鼠肝脏的改变进行了研究。与其性别依赖性致癌性一致，给予ZAMI 1305会导致雌性大鼠肝脏中的DNA损伤，但雄性大鼠不会，4只接受6天治疗的雄性大鼠中只有2只除外。在雌性大鼠中，DNA损伤量在治疗1天至6天期间增加，在10天时保持不变；然而，有一小部分DNA受到损伤。给雌性大鼠施用ZAMI 1305还会导致：（i）相对肝脏重量、DNA和RNA合成活性增加；（ii）有丝分裂期肝细胞数量减少；（iii）最小程度的卵圆细胞增生。当在接受ZAMI 1305治疗的雄性大鼠中研究相同参数时，它们未受影响或相对于雌性大鼠变化较小。
